Bavisant
As of the edition of 20 October 2026, Bavisant is a small molecule: went quiet in 2019; acts on HRH3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Small molecule
- Registered trials
- 8, 2 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Bavisant.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH3 | Histamine H3 receptor | Q9Y5N1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Lead sponsor of trials | 2009 to now |
| BenevolentAI Bio | Lead sponsor of trials | 2017 to now |